Regeneron Pharmaceuticals Inc (REGN) Receives Average Rating of “Hold” from Analysts

Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have earned an average rating of “Hold” from the thirty ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $469.27.

A number of analysts have commented on REGN shares. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, October 31st. Evercore ISI reduced their target price on Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating for the company in a report on Thursday, November 16th. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and cut their price objective for the stock from $450.00 to $395.00 in a report on Friday, October 20th. Guggenheim reaffirmed a “buy” rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 23rd. Finally, Morgan Stanley reaffirmed an “equal weight” rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th.

Regeneron Pharmaceuticals (NASDAQ:REGN) traded up $0.25 during trading on Friday, hitting $371.53. The company’s stock had a trading volume of 662,124 shares, compared to its average volume of 660,649. The company has a market cap of $39,920.00, a price-to-earnings ratio of 33.74, a price-to-earnings-growth ratio of 1.44 and a beta of 1.52. Regeneron Pharmaceuticals has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping the Zacks’ consensus estimate of $3.83 by $0.16. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter last year, the company earned $3.13 EPS. research analysts expect that Regeneron Pharmaceuticals will post 13.55 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REGN. Harding Loevner LP lifted its position in Regeneron Pharmaceuticals by 589.2% during the third quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after purchasing an additional 3,131,966 shares in the last quarter. Janus Henderson Group PLC lifted its position in Regeneron Pharmaceuticals by 15,495.4% during the second quarter. Janus Henderson Group PLC now owns 1,562,970 shares of the biopharmaceutical company’s stock valued at $767,637,000 after purchasing an additional 1,552,948 shares in the last quarter. FMR LLC lifted its position in Regeneron Pharmaceuticals by 6.3% during the second quarter. FMR LLC now owns 7,039,884 shares of the biopharmaceutical company’s stock valued at $3,457,569,000 after purchasing an additional 416,192 shares in the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in Regeneron Pharmaceuticals by 500,446.2% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 325,355 shares of the biopharmaceutical company’s stock valued at $145,472,000 after purchasing an additional 325,290 shares in the last quarter. Finally, PointState Capital LP purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at $78,199,000. Institutional investors own 66.63% of the company’s stock.

WARNING: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/01/19/regeneron-pharmaceuticals-inc-regn-receives-average-rating-of-hold-from-analysts.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply